Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL9311609 | 0.99 | AGTR1 (0.47) | AGTR1AGTR2 | |
| SCHEMBL9309262 | 0.96 | AGTR1 (0.42) | AGTR1AGTR2 | |
| SCHEMBL9309139 | 0.94 | AGTR1 (0.40) | AGTR1AGTR2 | |
| SCHEMBL9309518 | 0.93 | AGTR1 (0.38) | AGTR1AGTR2 | |
| SCHEMBL9309585 | 0.92 | AGTR1 (0.40) | AGTR1AGTR2 | |
| SCHEMBL9311339 | 0.92 | AGTR1 (0.40) | AGTR1AGTR2 | |
| SCHEMBL9309564 | 0.92 | AGTR1 (0.40) | AGTR1AGTR2 | |
| SCHEMBL9309706 | 0.92 | AGTR1 (0.40) | AGTR1AGTR2 | |
| SCHEMBL9309325 | 0.92 | AGTR1 (0.38) | AGTR1AGTR2 | |
| SCHEMBL9309579 | 0.92 | AGTR1 (0.39) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5374646-A | Treatment or prophylasix of hypertension and diseases associated with cognitive disorders | GLAXO GROUP LIMITED (GB) | 1994-12-20 | — | — | US | claimed |
| EP-0434249-A2 | Benzofuran derivatives | GLAXO GROUP LIMITED (GB) | 1991-06-26 | — | — | EP | claimed |
| US-20100048654-A1 | USE OF VALSARTAN OR ITS METABOLITE TO IN HIBIT PLATELET AGGREGATION | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-02-25 | — | — | US | disclosed |
| US-20090012052-A1 | METHOD FOR TREATING ER+ BREAST CANCER | ORE PHARMACEUTICALS INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080132474-A1 | BREAST CANCER SCREENING AND TREATMENT METHODS | GENE LOGIC INC. (US) | 2008-06-05 | — | — | US | disclosed |
| EP-0724387-B1 | ANGIOTENSION II RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC ANTI-INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORP (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6329384-B1 | CARDIOVASCULAR DISORDERS USING PYRAMIDINYLOXYDIPHENYL ALKYLCARBOXYLIC ACID | ABBOTT LABORATORIES | 2001-12-11 | — | — | US | disclosed |
| US-5696116-A | TREATING DISORDERS ASSOCIATED WITH VASOCONSTRICTION | HOFFMANN-LA ROCHE INC. (US) | 1997-12-09 | — | — | US | disclosed |
| US-5374646-A | Treatment or prophylasix of hypertension and diseases associated with cognitive disorders | GLAXO GROUP LIMITED (GB) | 1994-12-20 | — | — | US | disclosed |
| EP-0434249-A2 | Benzofuran derivatives | GLAXO GROUP LIMITED (GB) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048654-A1 | USE OF VALSARTAN OR ITS METABOLITE TO IN HIBIT PLATELET AGGREGATION | PDGFRA, PLAT, PTAFR | AGTR1 34/4885AGTR2 36/4885 |
| US-20080132474-A1 | BREAST CANCER SCREENING AND TREATMENT METHODS | PGR, AGTR1, AGTR2 | AGTR1 2/4885AGTR2 3/4885 |
| US-20090012052-A1 | METHOD FOR TREATING ER+ BREAST CANCER | PGR, ESRRB, ESR2 | AGTR1 10/4885AGTR2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.